EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Annual Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease During Infliximab Maintenance Therapy: Balancing Efficacy with Risk of Pharmacokinetic Failure

Yujin Lim, Boram Park, Kyeongman Jeon, Ok Soon Jeong, Eun Ran Kim, Young-Ho Kim, Dong Kyung Chang, Sung Noh Hong

Digestive Diseases and Sciences · 2025

DOI: 10.1007/s10620-025-09032-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive Diseases and Sciences, 2025. Verfasst von Yujin Lim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea. Hauptthemen laut MEDLINE: Infliximab, Drug Monitoring, Gastrointestinal Agents, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP), Future Medicine 20*30 Project of the Samsung Medical Center, Sungkyunkwan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIMS: Recent studies indicate that proactive therapeutic drug monitoring (TDM) can improve clinical outcomes in patients with inflammatory bowel disease (IBD) treated with infliximab. Repetitive infliximab trough level (IFX TL) measurements for proactive TDM may increase patient inconvenience and medical costs. Therefore, we aimed to determine the optimal interval for TDM during infliximab maintenance therapy in patients with IBD. METHODS: A prospective cohort study was performed on the patients with IBD who were in clinical remission on infliximab maintenance therapy and had IFX TL ≥ 3 μg/mL after one-time dose optimization. Infliximab TL were measured before each infliximab infusion to identify the pharmacokinetic (PK) relapse (two consecutive IFX TL < 3 μg/mL). Kaplan-Meier method was used to calculate the time to PK relapse. RESULTS: A total of 103 patients were enrolled and followed for a median of 18.5 months. PK relapse occurred in 19 patients (18.5%), with a higher rate of PK relapse in patients with IFX TL 3-5 μg/mL (16/60, 26.7%) compared to those with IFX TL ≥ 5 μg/mL (3/43, 7.0%). Kaplan-Meier survival time to maintain 95%, 90%, 85%, 80%, and 75% therapeutic IFX TL persistence rate without PK relapse was 4.1, 10.3, 13.3, 14.3, and 19.8 months, respectively. Log-rank test showed that therapeutic IFX TL persistence rates were significantly lower in patients with IFX TL 3-5 μg/mL group compared to those with IFX TL ≥ 5 μg/mL group (p = 0.010). Kaplan-Meier retention time to maintain 85% therapeutic IFX TL persistence rate without PK relapse was 10.3 months in IFX TL 3-5 μg/mL group and 20.2 months in IFX TL ≥ 5 μg/mL group, respectively. CONCLUSIONS: Proactive TDM measuring with IFX TL annually may be helpful in maintaining therapeutic IFX TL ≥ 3 μg/mL in 85% of patients with IBD and clinical remission on infliximab maintenance therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InfliximabDrug MonitoringGastrointestinal AgentsInflammatory Bowel DiseasesHumansFemaleMaleAdultProspective StudiesMiddle AgedMaintenance ChemotherapyRecurrenceYoung AdultTreatment Outcome

Stichwörter der Autor:innen

Inflammatory bowel diseasesInfliximabPharmacokinetic relapseTherapeutic drug monitoringTrough level

Substanzen

InfliximabGastrointestinal Agents

Autor:innen und Institutionen

  • Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.
  • Biomedical Statistics Center, Samsung Medical Center, Research Institute for Future Medicine, Seoul, Korea.
  • Department of Data Service Team, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea. sungnoh.hong@samsung.com.

Förderung

  • National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP)
  • Future Medicine 20*30 Project of the Samsung Medical Center
  • Sungkyunkwan University

Zitieren

APA

Lim, Y., Park, B., Jeon, K., Jeong, O. S., Kim, E. R., Kim, Y. H., Chang, D. K., & Hong, S. N. (2025). Annual Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease During Infliximab Maintenance Therapy: Balancing Efficacy with Risk of Pharmacokinetic Failure. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-025-09032-9

Vancouver

Lim Y, Park B, Jeon K, Jeong OS, Kim ER, Kim YH, et al. Annual Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease During Infliximab Maintenance Therapy: Balancing Efficacy with Risk of Pharmacokinetic Failure. Digestive Diseases and Sciences. 2025. doi:10.1007/s10620-025-09032-9

BibTeX
@article{Lim2025,
  author = {Lim, Yujin and Park, Boram and Jeon, Kyeongman and Jeong, Ok Soon and Kim, Eun Ran and Kim, Young-Ho and Chang, Dong Kyung and Hong, Sung Noh},
  title = {Annual Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease During Infliximab Maintenance Therapy: Balancing Efficacy with Risk of Pharmacokinetic Failure},
  journal = {Digestive Diseases and Sciences},
  year = {2025},
  doi = {10.1007/s10620-025-09032-9}
}
Kostenlos starten →